AFP and liver cancer: Additionally, estrogens can inhibit interleukin-6 by reducing activation via Myd88-induced nuclear factor kappa-B, thereby suppressing the progression of liver fibrosis and chronic liver disease.[19,24,25] Our study identified sex as an independent risk factor for missed diagnosis when screening for liver cancer using AFP and PIVKA-II.